Members of the erbB family of receptor tyrosine kinases are commonly overexpressed in human breast cancer. However, the relative contribution of particular signalling pathways activated downstream of these receptors to the mitogenic response of transformed breast epithelial cells remains poorly characterized. Administration of heregulin-b2 (HRG), a ligand for erbB3 and erbB4, to growth arrested T-47D human breast cancer cells leads to activation of both the PI3-kinase and MAP kinase signalling pathways and potent stimulation of cell cycle progression. Speci®c inhibitors were used to assess the role of these pathways in HRG-induced mitogenesis and to identify underlying mechanisms in terms of regulation of gene expression. Treatment with the MEK inhibitor PD98059 led to a complete block of HRG-induced entry into S-phase, whilst administration of the PI3-kinase inhibitor wortmannin resulted in only modest inhibition. In addition, administration of PD98059 8 h after HRG was equipotent with simultaneous administration in inhibiting entry into S-phase. However, delaying addition for 14 ± 16 h after HRG, when the cells were entering Sphase, was without eect. HRG stimulation led to sequential induction of c-myc, cyclin D1, cyclin E and cyclin A gene expression and hyperphosphorylation of the retinoblastoma protein pRB. p21 (WAF1/CIP1/ SDI1) gene expression was rapidly induced by HRG, but signi®cant changes in p27 (KIP1) protein levels were not detected. Preincubation with PD98059 blocked the HRG-dependent induction of cyclin D1 mRNA, p21 and c-Myc protein and pRB phosphorylation. These ®ndings demonstrate that MEK activation is critical to HRGinduced S-phase entry in these cells whilst PI3-kinase plays a minor role. Moreover, these data are compatible with HRG-induced activation of MEK being critical for a mid-G1 transition point and implicate c-myc and cyclin D1 as key targets of the MAP kinase pathway involved in this response.
Introduction
The erbB family of receptor tyrosine kinases (RTKs) consists of four members: the epidermal growth factor receptor (EGFR or erbB1), erbB2, erbB3 and erbB4 (erb2-4). Signalling by these RTKs is strongly implicated in the development and progression of breast cancer. For example, high expression of the EGFR in this disease has been proposed as a predictor of early recurrence and death (Sainsbury et al., 1987) and ampli®cation and/or overexpression of the erbB2 gene occurs in 20 ± 30% of human breast cancers and is associated with decreased patient survival (Slamon et al., 1989) . Furthermore, expression of the erbB2 oncogene under the control of the MMTV promoter causes the frequent development of mammary tumours in transgenic mice (Muller et al., 1988) . Finally, high expression of the erbB3 and erbB4 genes has been detected in human breast cancer cell lines (Kraus et al., 1989; Plowman et al., 1990 Plowman et al., , 1993a .
Signalling by the erbB family is regulated at several levels. First, a variety of receptor ligands exists with distinct speci®cities for one or more family members. For example, the EGFR possesses multiple ligands, including EGF, TGFa and amphiregulin and references therein), whilst both erbB3 and erbB4 provide receptors for the heregulin (HRG)/ neuregulin 1 (NRG1) and NRG2 families of ligands (Carraway et al., , 1997 Plowman et al., 1993b; Sliwkowski et al., 1994; Tzahar et al., 1994; Chang et al., 1997) . Also, erbB family receptors exhibit both qualitative and quantitative dierences in signalling potential. For example, erbB3 recruits and activates PI3-kinase more potently than the EGFR or erbB2 (Fazioli et al., 1991; Fedi et al., 1994; Hu et al., 1992; Prigent and Gullick, 1994) . Finally, ligand-induced receptor heterodimerization occurs in a hierarchical fashion, diversifying the signals that can be generated by particular ligands Riese et al., 1995; Tzahar et al., 1996) .
Two key signalling intermediates activated in response to stimulation of particular erbB receptors are PI3-kinase and the low molecular weight G protein Ras. Regulation of the former occurs through receptor recruitment of the p85 subunit leading to stimulation of the activity of the p110 catalytic subunit (Kapeller and Cantley, 1994; Fedi et al., 1994; Prigent and Gullick, 1994; Kim et al., 1994; Solto et al., 1994) . This enzyme is involved in a variety of cellular responses to RTK activation, including proliferation, membrane ruing, protein sorting and prevention of apoptosis (reviewed in Kapeller and Cantley, 1994; Hemmings, 1997; Franke et al., 1997) . Activation of Ras is mediated by binding of complexes between the adaptor protein Grb2 and the Ras GDP ± GTP exchange protein Sos to either particular receptors or Shc Janes et al., 1994; Fiddes et al., 1995) and plays a pivotal role in regulation of cellular proliferation and dierentiation (reviewed in .
A well characterized eector pathway downstream of Ras is the mitogen-activated protein (MAP) kinase cascade. Conversion of Ras to the GTP-bound state activates a serine/threonine kinase (Raf), which phosphorylates and activates a dual-speci®city protein kinase (MAP kinase kinase, MEK), which in turn phosphorylates and activates the serine/threonine directed MAP kinases or extracellular signal-regulated protein kinases 1 and 2, Erk1/2. The latter are activated by diverse external stimuli and by protooncogene products that induce proliferation or dierentiation (reviewed in Blenis, 1993; Cobb et al., 1994; Cobb and Goldsmith, 1995) . The extent and duration of Erk1/2 activation may specify the particular cellular response (reviewed in Marshall, 1995) . Recently, a synthetic compound, PD98059, has been described that acts in vivo as a selective inhibitor of MEK and the MAP kinase cascade (Alessi et al., 1995; Dudley et al., 1995; Pang et al., 1995) . PD98059 binds to the inactive form of MEK, blocking its activation by Raf and has been tested in vitro and in vivo on more than 25 closely related kinases, none of which show signi®cant inhibition (Alessi et al., 1995; Dudley et al., 1995; Lazar et al., 1995) .
In ®broblasts, sustained activation of Erk1/2 is required for cells to pass the G 1 restriction point (Pages et al., 1993) . Increasing evidence suggests that the downstream targets linking this signalling pathway to cell cycle control include cyclin D1 and c-myc. The nuclear transcription factor c-myc is induced following MAP kinase activation; this protein is both necessary and sucient for resting cells to enter the cell cycle (reviewed by Vastrik et al., 1994) . Induction of cyclin D1 is an early event following mitogen stimulation of the G 0 /G 1 to S-phase transition. The consequent activation of cyclin D1-associated cyclin-dependent kinases (CDKs) and phosphorylation of speci®c targets including pRB, the product of the retinoblastoma susceptibility gene, is essential for entry into Sphase (Weinberg, 1995; Sherr, 1996; Sherr and Roberts, 1995) . However, while cyclin D1-associated CDKs are important pRB kinases, other CDKs also phosphorylate pRB. These include cyclin E/Cdk2, which is activated late in G 1 , and cyclin A/Cdk2, activated upon entry into S-phase. Inhibition of Erk1/2 signalling downregulates cyclin D1 expression and activation of the Erk1/2 cascade is sucient to induce cyclin D1, although not to promote phosphorylation of pRB (Lavoie et al., 1996; Albanese et al., 1995) . MAP kinase activation has also been implicated in the transcriptional activation of p21 (WAF1, CIP1) following growth factor stimulation (Liu et al., 1996) . Since this protein and the related p27 (KIP1) were initially identi®ed as CDK inhibitors (Sherr, 1996; Sherr and Roberts, 1995) , induction following mitogenic stimulation was unexpected. However, cyclin/ CDK complexes containing p21 or p27 are not necessarily inactive (Zhang et al., 1994; Soos et al., 1996; LaBaer et al., 1997) and these proteins may function as adaptors facilitating the assembly of cyclin D/CDK complexes (LaBaer et al., 1997) . Thus induction of p21 may contribute to activation of the cyclin D/pRB pathway.
Previously, we reported that administration of HRGb2 to breast cancer cells overexpressing erbB2-4 triggered multiple inputs into the Ras pathway and led to erbB3-mediated activation of PI3-kinase (Fiddes et al., 1995) . Furthermore, HRGb2 stimulated the proliferation of these breast cancer cell lines and when tested for the ability to stimulate cell cycle re-entry of T-47D cells arrested under serum-free conditions, induced a semisynchronous entry of cells into S-phase. In the studies described herein we used speci®c inhibitors of PI3-kinase and of MAP kinase activation to ascertain the contribution of these pathways to HRG-induced cell cycle progression in human breast cancer cells. The role of MAP kinase signalling in regulation of key early response genes and components of the cell cycle machinery was also investigated. The resulting data indicate a critical role for MAP kinase, but not PI3-kinase, in HRGinduced mitogenic signalling in these cells.
Results

Cell cycle progression
To examine the eect of inhibition of PI3-kinase activity or Erk1/2 activation on HRG-induced mitogenesis, growth-arrested T-47D cells were treated with HRG in the presence of inhibitors of these pathways and the S-phase fraction measured. T-47D cells were chosen because they express moderate levels of erbB receptors with low baseline receptor activation. In addition, we have previously shown that HRG is a potent mitogen and activator of cell cycle progression in T-47D cells (Fiddes et al., 1995) . Similar to the previously reported results, HRG stimulated the semisynchronous entry of T-47D cells into S-phase, such that the S-phase fraction reached a peak of 33 ± 38% 24 h after the addition of HRG (Figure 1 ). Preincubation with the MEK inhibitor PD98059 for 30 min before HRG stimulation blocked the stimulatory eect in a concentration-dependent manner. Up to 30 mM PD98059 had no signi®cant inhibitory eect on HRG stimulation of entry into S-phase, while maximum inhibition was seen at 550 mM where S-phase remained at control levels (13 ± 16%). In this context PD98059 exhibited an IC 50 value of 38 mM. DNA histograms (Figure 2 ) revealed that serum deprivation of T-47D cells resulted in a G 1 block with 70 ± 75% of cells in G 1 , 12 ± 16% S-phase and 12 ± 15% G 2 /M. HRG stimulation resulted in cell cycle progression as described above and preincubation with PD98059 blocked the increase in the fraction of cells in S-phase, with no apparent accumulation of cells in G 2 /M. This demonstrates that PD98059 acts exclusively in G 1 to inhibit entry into S-phase. In contrast to the eects of PD98059, wortmannin treatment only partially blocked the HRG-induced cell progression (Figure 1 ). Pretreatment with wortmannin (50 ± 200 nM) reduced the HRG-induced entry of cells into S-phase by 30 ± 35%. While 400 nM wortmannin was slightly more eective, at this concentration inhibition of phospholipase A2 activity (Cross et al., 1995) or other kinases (Powis et al., 1994) , may contribute to its eect.
We repeated these experiments in ZR-75-1 breast cancer cells and found that HRG stimulated cell cycle progression from a control level of 10% to 28% Sphase. Preincubation with PD98059 reduced the HRGinduced cell cycle progression in a concentration dependent manner, with a maximum eect at 550 mM, to 16% S-phase. However, wortmannin (100 nM) did not signi®cantly inhibit cell cycle progression. Consequently, similar to T-47D cells, this suggests that the MAP kinase pathway, and not signalling by PI3-kinase, plays a major role in HRGinduced cell cycle progression in breast cancer cells. The failure of PD98059 to completely block HRGstimulated cell cycle progression is possibly due to the inability of PD98059 to completely block a more potent MAP kinase stimulation, since ZR-75-1 cells express signi®cantly higher levels of erbB2 and erbB4 than T-47D cells (deFazio, Janes and Fiddes, unpublished results) .
To con®rm that the eects of PD98059 were not due to cell toxicity, we investigated the eect of this compound on serum-induced cell cycle progression. Addition of FCS (10%) to growth arrested T-47D cells resulted in an S-phase fraction of 30% after 24 h. Pretreatment with PD98059 (50 mM) reduced this to 24% (Figure 1 ). This partial inhibition of serum- induced cell cycle progression compared to the complete block of that seen in HRG stimulated cells con®rms that the potent eects of PD98059 in the latter setting are not non-speci®c.
MAP-kinase and PI3-kinase activation
Since HRG-induced cell cycle progression in T-47D cells was blocked completely by PD98059, all subsequent experiments were performed using these cells. To con®rm that PD98059 inhibited Erk1/2 activation at concentrations that blocked cell cycle progression, total cell lysates were analysed by Western blot for erbB receptor activation (using anti-phosphotyrosine antibodies), and MAP kinase activity using antibodies speci®c for total Erk1/2 and activated (phosphorylated) Erk1/2. Phosphorylation of erbB receptors ( Figure 3a , upper panel) and Shc (data not shown) was apparent 10 min following HRG treatment which also increased the levels of activated Erk1/2 to 8 ± 10-fold (representative of three experiments) that of non-treated cells (lower panel). Total Erk1/2 levels were the same for control and HRG-treated cell lysates (middle panel). Also, the total Erk1/2 protein from HRG-treated cells displayed reduced mobility on SDS ± PAGE gels indicating that the majority of MAP-kinase present in these cells was in a phosphorylated state. However, cells preincubated with PD98059 (50 mM), 30 min before HRG stimulation, did not exhibit subsequent Erk1/2 activation compared with untreated controls, despite tyrosine phosphorylation of erbB receptors (Figure 3a) . The low basal level of Erk1/2 activation observed in serum starved cells was also reduced by PD98059 addition (Figure 3a , lower panel).
In Figure 3b , we investigated the concentrationdependence of Erk1/2 inhibition by PD98059. Interestingly, 10 mM PD98059 signi®cantly inhibited HRG-induced Erk1/2 activation, although an approximately threefold increase over the controls was still apparent. However, 50 mM PD98059 reduced the activation of Erk1/2 to baseline levels. Since this is the minimum concentration of PD98059 required to completely block cell cycle progression, we assume that the signi®cant activation of Erk1/2 evident at 10 ± 30 mM PD98059 is sucient to mediate this response. However, the above response was determined 10 min following HRG stimulation and experiments described later in the manuscript indicate that Erk1/2 activity is required for a minimum of 8 h for ecient cell cycle progression (Figure 7) . Consequently, the stability of the compound over this time frame may limit its ecacy, particularly at low concentrations.
To con®rm that HRG treatment leads to activation of PI3-kinase, association of this enzyme activity with HRG-activated erbB receptors was investigated. In an in vitro assay, speci®c erbB receptor immunocomplexes from lysates of control or HRGstimulated T-47D cells were evaluated for the ability to phosphorylate PI in the presence of [g 32 P]ATP. A strong kinase activity was associated with erbB3 ( Figure 4 ), but not erbB2 (data not shown) and this was completely blocked by 100 nM wortmannin, indicating that the phosphorylation of PI in the assay was due speci®cally to PI3-kinase. Importantly, growth factor stimulation of PI3-kinase activity is also completely blocked by 100 nM wortmannin in vivo (Franke et al., 1995) .
Overall, these data indicated a minor role for PI3-kinase but a major involvement of MEK in HRGinduced mitogenesis. Further experiments therefore concentrated on identifying which HRG-induced events were dependent on the MAP kinase cascade.
Cyclin gene expression
Cell lysates taken at progressive time points after HRG stimulation of growth-arrested T-47D cells were analysed for cyclin gene expression. HRG treatment
Erk1-P* Erk2-P* a b . Cyclin E expression was not signi®cantly changed at 2, 4 and 8 h after HRG treatment but after 24 h HRG stimulated cyclin E mRNA and protein expression levels to 5 ± 6-fold higher than untreated growth-arrested cells ( Figure 5 ). Similarly, cyclin A mRNA levels were unchanged at 2, 4 and 8 h but increased 35 ± 40-fold 24 h after the addition of HRG to growth-arrested T-47D cells ( Figure 5 ) consistent with the signi®cant fraction of S-phase cells at that time (Figure 1 ). Thus, as expected, induction of cyclin D1 preceded induction of the other cyclin genes examined. This sequential induction of cyclin gene expression (Figure 5c ) is similar to that observed following treatment of these cells with other growth factors and is consistent with our previously described (Fiddes et al., 1995) induction of cell cycle progression as early as 18 h after HRG addition, as indicated in Figure  5c .
To determine the contribution of MAP kinase activation to cyclin D1 induction we examined the eects of PD98059 on HRG-induced cyclin D1 expression. The inhibitor alone had no detectable eect on the basal level of cyclin D1 expression but the stimulation of cyclin D1 mRNA seen at 8 h following HRG addition was completely blocked upon preincubation with PD98059 ( Figure 6 ). These data implicate cyclin D1 as a likely downstream target of HRG-activated MAP kinase.
PD98059 directly blocks HRG-induced cyclin D1 mRNA up-regulation
Since cyclin D1 is necessary for G 1 progression until near the G 1 -S-phase boundary (Baldin et al., 1993) , we investigated the potential role of MAP kinase activation in this process. To this end the eect of delayed administration of PD98059 on S-phase entry was studied. Addition of PD98059, 8 h after HRG stimulation had essentially the same eect as simultaneous administration (Figure 7a) . Further delaying addition of the inhibitor to between 10 and 12 h was partially eective whereas delaying administration beyond 14 h, when the ®rst HRG-stimulated cells were entering S-phase, had no eect. These data show that HRG-induced stimulation of MAP kinase was required for at least 8 h before cells become committed to S-phase entry and that PD98059 was without eect on cells in late G 1 , S or G 2 /M-phases. To determine whether the PD98059 block of HRG-induced upregulation of cyclin D1 was due to the block of cell cycle progression, we evaluated whether cells committed to cell cycle progression at 14 h post HRG treatment experienced a reduction in cyclin D1 levels upon PD98059 exposure (Figure 7b) . At 18 h after HRG stimulation (4 h post PD98059), cyclin D1 levels were 30% less than HRG treated controls. A more dramatic dierence was seen at 24 h after HRG stimulation (8 h post PD98059) where cyclin D1 levels were indistinguishable from control levels, that is, 3 ± 4-fold lower than those in cells treated with HRG alone. These results suggest that the downregulation of HRGinduced cyclin D1 expression by PD98059 is a consequence of the inhibition of the MAP kinase pathway rather than a block of cell cycle progression, since PD98059 had little eect on cell cycle progression when administered at this time.
CDK inhibitors
Since a role for MAP kinase in the transcriptional activation of p21 following growth factor stimulation has been demonstrated in HeLa and PC12 cells (Liu et al., 1996) , and p27 may have a role in cyclin/CDK complex formation (LaBaer et al., 1997), we investigated the eects of HRG in the presence or absence of PD98059 on the expression of p21 and p27. HRG rapidly induced both p21 protein and mRNA in growth-arrested T-47D cells (Figure 8 ). However, although only a twofold increase in p21 mRNA relative to control cells was observed after 2 h HRG treatment, p21 protein increased 5 ± 6-fold (range over two experiments). Following 4 h HRG treatment p21 protein levels were still 2 ± 3-fold higher than control cells but by 24 h p21 expression had returned to control levels. When HRG was added to growtharrested T-47D cells we did not observe any signi®cant changes in p27 protein levels at 2 or 4 h after HRG addition (Figure 8 ). Although in some experiments there was a 30 ± 40% reduction at 24 h, this was not a consistent ®nding.
To investigate whether Erk1/2 were involved in p21 induction, p21 protein and mRNA levels were determined in cells preincubated with PD98059. The HRG-stimulated increase in p21 expression was blocked by PD98059 at both 2 and 4 h, whereas Figure 4 HRG stimulation of erbB3-associated PI3-kinase activity in T-47D cells. Growth-arrested T-47D cells were stimulated, or not, with HRG (5 nM). Cell lysates were collected 15 min after HRG stimulation and erbB3 immunoprecipitates were assayed for kinase activity using PI as the substrate in the presence or absence of wortmannin (100 nM). Phospholipid products were separated by thin layer chromatography with PI and PI4'P standards. Results are representative of at least two experiments administration of the inhibitor alone at these time points had no eect.
PI3-P origin
c-myc induction
A response common to steroid and polypeptide mitogens in human breast cancer cells is induction of the nuclear transcription factor c-myc in early G 1 phase of the cell cycle (reviewed by Vastrik et al., 1994) . When HRG was added to growth-arrested T-47D cells, c-myc expression at both the mRNA and protein level was stimulated (Figure 8 ). c-myc mRNA levels were 5 ± 6-fold (range over two experiments) higher than control cultures, 2 h after HRG adminis- RNA and protein were also extracted from cells cultured in normal growth medium containing 10% FCS (10% FCS). Expression of cyclin D1 (D1), cyclin E (E) and cyclin A (A) mRNAs were determined by Northern blot analysis using 32 P-labelled cDNA probes (a). Western blot analysis was performed using speci®c monoclonal antibodies (b). (c) is a graphical representation of mRNA expression, relative to 18S levels, determined by densitometric analysis; cyclin D1 (&), cyclin E (*), cyclin A (*). Results are representative of at least two experiments tration. This stimulation was partially blocked by preincubation with PD98059, resulting in an increase 2 ± 3-fold over controls. At the protein level, c-Myc was up-regulated at both 2 h (3 ± 4-fold over controls) and 4 h (twofold) after HRG administration ( Figure  8 ). Preincubation with PD98059 completely blocked the HRG-stimulated increase in c-Myc protein at 2 h.
Rb protein phosphorylation
To con®rm that the cyclin induction documented in Figure 5 was associated with CDK activation and pRB phosphorylation, the latter was examined following HRG stimulation. Since phosphorylated pRB exhibits reduced mobility on SDS ± PAGE gels, total cell lysates were analysed by Western blot. In growth-arrested T-47D cells, 80 ± 90% (range over three experiments) of pRb was hypophosphorylated (Figure 9 , upper panel). HRG stimulation resulted in an increased level of hyperphosphorylated pRb, apparent at 8 h but maximal 24 h after the addition of HRG when 60 ± 65% of pRb was hyperphosphorylated. In cells preincubated with PD98059, 90 ± 95% of pRb was hypophosphorylated, in either the presence or absence of HRG (Figure 9 , lower panel). This indicates that not only was the HRG-stimulated hyperphosphorylation of pRb blocked by PD98059, but also that PD98059 decreased the basal level of pRb phosphorylation. This is perhaps due to the block of basal MAP kinase activity present in the growth-arrested T-47D cells (Figure 3 ).
Discussion
Using a system of T-47D human breast cancer cells growth-arrested under serum-free conditions, we previously described that the HRGs were particularly potent at inducing cell cycle progression (Fiddes et al., 1995) . Since HRG administration to these cells leads to activation of both the PI3-kinase and MAP kinase signalling pathways (Fiddes et al., 1995; Marte et al., 1995a,b; Janes, unpublished results) , the object of this study was to assess the relative contribution of these pathways to HRG-induced mitogenesis and to investigate the mechanisms (in terms of regulation of gene expression) underlying their eects. Preincubation of the cells with PD98059 at concentrations sucient to completely inhibit Erk1/2 activation (Figure 3) blocked HRG-induced cell cycle progression, whilst preincubation with wortmannin, at concentrations which completely blocked PI3-kinase activity (Figure 4) , resulted in only slight inhibition (Figure 1) . These results therefore indicate that in this model system, MAP kinase activation is critical to HRG-induced entry into S-phase, whilst the contribution from PI3-kinase is more modest. Interestingly, HRG-induced MAP kinase activation in T-47D cells is more sensitive to PD98059 administration than that triggered by the EGFR in Swiss 3T3 cells (Alessi et al., 1995) , which probably re¯ects dierent magnitudes of activation of this cascade by particular erbB receptors or receptor combinations. Also of note in this regard is that the proliferation of EGFR-transformed 3T3 cells was relatively insensitive to this inhibitor . In contrast, the eect of wortmannin on HRG-induced cell cycle progression in T-47D and ZR-75-1 cells is less than that observed in other studies investigating erbB receptor signalling via PI3-kinase.
For example, wortmannin inhibited HRG-induced DNA synthesis in ®broblasts transfected with erbB2 and erbB3 (Carraway et al., 1995) by 45% and completely blocked the growth factor-independent proliferation of 21-MT human breast cancer cells, which express erbB3 and high levels of erbB2 (Ram and Ethier, 1996) . Dierences between the cell lines used in these studies, particularly in terms of their relative levels of erbB receptors, and the responses investigated (i.e. HRG-induced rather than basal cellular proliferation) may explain this variation. Nonetheless both cell lines studied (T-47D and ZR-75-1), which are representative of the more differentiated hormone-responsive phenotype, responded similarly to PD98059 suggesting that signalling through MAP kinase is the predominant pathway for HRGinduced mitogenesis in this breast cancer phenotype.
Recently some controversy has arisen as to whether PI3-kinase is upstream or downstream of Ras. Active Ras binds to the p110 subunit of PI3-kinase and stimulates its activity in vivo (Rodriguez-Viciana et al. 1994; Kodaki et al., 1994) . However, expression of a constitutively activated form of PI3-kinase activates Ras and induces Ras-dependent maturation in Xenopus oocytes (Hu et al., 1995) . Furthermore, inhibition of PI3-kinase inhibits PDGF-stimulated MAP kinase activity in hepatic stellate cells (Marra et al., 1995) . In the T-47D and ZR-75-1 model system, comparison of the inhibitory eects of PD98059 and wortmannin indicate that PI3-kinase does not play a major role in MAP kinase activation, which is further supported by preliminary experiments demonstrating a lack of inhibition of Erk1/2 activation by wortmannin in T-47D cells (Janes, unpublished results) . It is therefore more likely that PI3-kinase is activated in parallel with Ras (e.g. by interaction with erbB3) and/or downstream of Ras and contributes to mitogenic signalling in a MAP kinase independent manner, for example through activation of p70 S6 kinase (Burgering and Coer, 1995; Klippel et al., 1996) . To gain a mechanistic insight into the role of Erk1/2 in HRG-stimulated S-phase entry, we investigated the role of these enzymes in the regulation of key cell cycle regulatory genes and the early response gene c-myc. In terms of cyclin gene expression, cyclin D1 mRNA was induced ®rst, increasing signi®cantly at 4 h and reaching a maximum level 8 h after HRG stimulation, followed by cyclin E and cyclin A ( Figure 5 ). This temporal pattern of cyclin gene expression is similar to that induced by other growth factors in growtharrested T-47D cells . HRG also induced a signi®cant increase in the level of both c-Myc and p21 protein 2 h after HRG addition ( Figure  8 ). Preincubation with PD98059 completely blocked the HRG-stimulated up-regulation of cyclin D1 mRNA and both c-Myc and p21 protein expression (Figures 6 and 8) . Delaying administration of PD98059 for several hours after HRG demonstrated a requirement for sustained activation of MAP kinase activation for at least 8 h to assure maximal progression into S-phase. However, when the majority of cells had entered S-phase at 16 ± 18 h, inhibition of MEK failed to aect subsequent cell cycle progression despite retaining the ability to inhibit cyclin D1 expression. Thus the eect of PD98059 on cyclin D1 results from inhibition of MAP kinase rather than as a consequence of inhibition of cell cycle progression. These data indicate a speci®c requirement for MAP kinase activity in early to late G 1 phase for HRGinduced mitogenesis. This eect of PD98059 on cyclin D1 expression is consistent with recent studies demonstrating upregulation of cyclin D1 expression by oncogenic Ras (Winston et al., 1996; Filmus et al., 1994; Liu et al., 1995) or MAP kinase activation (Lavoie et al., 1996; Albanese et al., 1995) . Stimulation of the cyclin D1 promoter through MAP kinase activation is thought to be mediated by c-Ets-2 binding to the proximal 22 bp of the cyclin D1 promoter (Albanese et al., 1995) . However, the cyclin D1 promoter also contains AP1 sites, and its activity is dierentially regulated by particular AP1 proteins, being upregulated by c-Jun and downregulated by c-Fos (Albanese et al., 1995) . The acute sensitivity of HRG-induced cyclin D1 expression to MEK inhibition despite the presence of these sites in the cyclin D1 promoter may be due to a lack of stimulation of the JNK pathway, and hence stimulation of c-Jun activity, by HRG in these cells (Fiddes, unpublished results) .
A critical target for phosphorylation by active cyclin D1/Cdk4 complexes is pRB. Indeed, in cycling cells, inactivation of Ras (and hence downregulation of cyclin D1) causes G 1 arrest in a pRb-dependent manner (Peeper et al., 1997) . Following HRG stimulation of growth-arrested T-47D cells, increased phosphorylation of pRB was ®rst evident at 8 h (Figure 9) , coincident with the peak of cyclin D1 mRNA and protein expression ( Figure 5 ), and by 24 h 60 ± 65% was hyperphosphorylated. Since cyclin D1 expression had declined by 24 h but cyclin E expression was maximal, this is consistent with progressive phosphorylation of pRB by cyclin D1-then cyclin E-dependent kinase complexes (Weinberg, 1995; Sherr, 1996; Sherr and Roberts, 1995) . Treatment with PD98059 completely blocked HRG-induced pRB hyperphosphorylation (Figure 9 ), indicating that the formation of these active pRB-kinase complexes was Erk1/2-dependent. Clearly a major explanation for this eect is the block of cyclin D1 induction by the inhibitor. However, PD98059 also blocks c-myc induction by HRG and the delineation of roles for c-Myc in activation of G 1 CDKs provides additional potential mechanisms. For example, recent data suggest that the activity of the CDK-activating phosphatase Cdc25A is limiting in serum-starved rodent ®broblasts (Steiner et al, 1995) . Cdc25A is a transcriptional target for c-myc and can be activated in a Raf-dependent manner, perhaps contributing to the co-operation between Myc and Ras in activation of cyclin E/Cdk2 (Galaktionov et al., 1995 (Galaktionov et al., , 1996 Leone et al., 1997) . Thus failure to induce or activate Cdc25A may contribute to the lack of pRB phosphorylation in the presence of PD98059. Furthermore, induction of cyclin E and sequestration of p27 in a form not available for cyclin E/Cdk2 binding, have been implicated as essential aspects of the mitogenic functions of c-Myc (Jansen- Durr et al., 1993; Vlach et al., 1996; Perez-Roger et al., 1997; Prall et al., 1998) . These mechanisms would be expected to be absent in the presence of PD98059.
A further mechanism for regulation of G 1 CDK activity is via the abundance and activity of CDK inhibitors. Our data demonstrating inhibition of HRGstimulated p21 induction by PD98059 con®rm the ®ndings of Liu et al. (1996) that the p21 promoter is stimulated by MAP kinase activation, and demonstrate an alternative pathway for HRG regulation of p21 expression in human breast cancer cells to the p53-dependent mechanism suggested by Bacus et al. (1996) . A marked increase in the expression of this CDK inhibitor under conditions where cyclin D1/CDK complexes are apparently activated can be explained by the recent demonstration of a role for p21 in the assembly of such complexes (LaBaer et al., 1997) . Two studies have indicated a potential requirement for downregulation of p27 expression in progression through G 1 and into S-phase. Expression of Ha-Ras in ®broblasts was insucient to induce DNA synthesis in serum starved cells, but supplementation with plasma factors resulted in a marked reduction in p27, maximal activation of cyclin D1/CDK and cyclin E/CDK complexes, and progression into S-phase (Winston et al., 1996) . Also, the co-operation between c-Myc and Ha-Ras in inducing cell cycle progression of REF52 cells correlated with loss of p27 expression, which was not seen upon expression of either protein alone (Leone et al., 1997) . Interestingly, although HRG administration was extremely potent in inducing cell cycle progression of growth-arrested T-47D cells, this occurred without a signi®cant decrease in p27 expression (Figure 8) . Variation in the expression levels of the dierent cyclins, CDKs and CDK inhibitors between the systems under investigation could explain this diering requirement for p27 downregulation.
In summary, our ®ndings demonstrate that activation of Erk1/2 is critical to HRG-induced mitogenesis in human breast cancer cells, and implicate cyclin D1 and c-myc as key targets of the MAP kinase pathway involved in this response. Since MAP kinase is frequently both upregulated and activated in human breast cancer (Janes et al., 1994; Sivaraman et al., 1997) this further highlights the potential of this signalling pathway as a target for therapeutic intervention.
Materials and methods
Reagents
Recombinant HRG, comprising the EGF-like domain of human HRGb2 (amino acids 177 ± 242) was produced as previously described (Fiddes et al., 1995) . PD98059 was purchased from New England Biolabs and reconstituted in DMSO. Wortmannin was purchased from Sigma and reconstituted in DMSO.
Cell culture
T-47D and ZR-75-1 human breast cancer cells were maintained in RPMI 1640 containing 10% FCS and 0.25 U/ml insulin. To generate growth-arrested semisynchronous cultures, T-47D cells were transferred to tissue culture¯asks at 1.8610 4 cells/cm 2 in phenol redfree RPMI 1640 containing 1% charcoal stripped FCS for 3 days or in phenol red-free, serum-free RPMI containing 200 nM transferrin for 7 days . Similar results were obtained using either experimental design. ZR-75-1 cells were transferred to tissue culture¯asks at 4.0610 4 cells/cm 2 in phenol red-free RPMI 1640 containing 5% charcoal stripped FCS for 2 days. PD98059 or wortmannin was added to cultures 30 min before the addition of HRG (5 nM ®nal concentration) according to the required protocol, except for the experiment described in Figure 7 where PD98059 was added after HRG addition at the times indicated. In all experiments, control cultures received vehicle alone.
Flow cytometry
Cells were harvested (using trypsin/EDTA) 24 h after the addition of HRG, with or without preincubation with inhibitors, and cell cycle phase distribution determined as previously described (Musgrove et al., 1989) .
Northern blots
Total RNA was isolated by the acid-phenol method. After electrophoresis on formaldehyde-agarose gels and transfer to a nitrocellulose membrane, mRNA expression levels were evaluated using a random primer-labelled cDNA probe, corresponding to the entire coding regions of cyclin A, cyclin D1, cyclin E, p21 and c-myc, as previously described (Alexander et al., 1989; Musgrove et al., , 1997 . RNA loading was evaluated by hybridizing membranes with a g-32 P-ATP end-labelled oligonucleotide complementary to 18S rRNA (Chan et al., 1984) . Hybridizations were performed overnight at 458C, followed by high stringency washing (0.26SSC/1% SDS at 658C) and autoradiography at 7808C using intensifying screens. Relative mRNA levels were determined by densitometry.
Western blots
Cell cultures were rinsed in cold PBS and solubilised in lysis buer, as previously described (Fiddes et al., 1995) . Cell lysates were separated by SDS ± PAGE, transferred to nitrocellulose and analysed by Western blot using antibodies speci®c for phosphorylated tyrosines (PY20, Transduction Labs), MAP-kinase and phosphorylated MAP-kinase (polyclonal antibodies #9102 and #9101, New England Biolabs), pRb (#14001A, PharMingen), cyclin D1 (CC11, Oncogene Sciences), cyclin E (sc-198, Santa Cruz Biotechnology), p21 (C24420, Transduction Laboratories), p27 (K25020, Transduction Laboratories), and c-Myc (9E11, Novocastra Laboratories). Detection of bound antibody was by ECL (Renaissance, NEN Life Sciences). Estimation of relative signal strength was determined by densitometry (Personal Densitometer SI, Molecular Dynamics).
PI3-kinase activity assay erbB3 protein was immunoprecipitated from cell lysates of HRG-treated or control T-47D cells using an anti-erbB3 monoclonal antibody (2F12, a gift from Dr JG Koland, The University of Iowa). PI3-kinase activity was assayed using a previously described method (Fiddes et al., 1995) .
